Mounjaro Alternatives & Comparison

Mounjaro (tirzepatide) wins on weight loss and A1C: SURPASS-2 head-to-head at 40 weeks showed Mounjaro 15mg -11.2 kg vs Ozempic 1mg -5.7 kg, and a 2.30% A1C drop vs 1.86%. Ozempic wins on cardiovascular outcomes — SUSTAIN-6 demonstrated a 26% reduction in MACE in T2D patients; Mounjaro's SURPASS-CVOT reads out in 2027. Both are FDA-approved for type 2 diabetes only; chronic weight management requires Wegovy or Zepbound. Choose based on glycemic-magnitude vs proven CV protection.

Mounjaro (tirzepatide) is Lilly's successor to Trulicity (dulaglutide) and outperforms it on every glycemic and weight axis — SURPASS-2 and SURPASS-3 placed Mounjaro 15 mg at ~2.3% A1C reduction and ~12 kg weight loss vs Trulicity 1.5 mg's roughly 1.1% A1C drop and ~3 kg in legacy AWARD trials. Trulicity holds three niche advantages: a proven cardiovascular outcome benefit (REWIND, MACE −12%), a pediatric T2D indication (ages 10+), and renal-impairment evidence from AWARD-7. Mounjaro's SURPASS-CVOT reads out in 2027.

Mounjaro is the more potent type 2 diabetes drug by a wide margin: SURPASS-2 showed Mounjaro 15 mg lowered A1C 2.30% and weight 11.2 kg vs oral semaglutide-equivalent comparators near 1.0% A1C and 4 kg. Rybelsus wins only on route — it is the sole FDA-approved oral GLP-1, taken daily on an empty stomach with no more than 4 oz of water and a 30-minute fast. Both are labeled for T2D only; neither is FDA-approved for weight loss. Pick Mounjaro for magnitude, Rybelsus for needle aversion.

Mounjaro and Zepbound are pharmacologically identical — both are tirzepatide manufactured by Eli Lilly. The split is regulatory: Mounjaro carries the FDA label for type 2 diabetes (SURPASS program), while Zepbound carries the labels for chronic weight management (SURMOUNT-1) and obstructive sleep apnea (SURMOUNT-OSA). LillyDirect cash prices are functionally identical at $349 starter / $499 maintenance. The right brand depends on which indication your insurance will cover.